The Global Divide in Cancer Care: The Impact of Keytruda Pricing

A medical breakthrough is only as effective as its accessibility. Keytruda (pembrolizumab), a powerhouse of modern immunotherapy, has fundamentally changed the trajectory of cancer treatment. However, a massive international investigation has revealed that the drug’s success is overshadowed by a stark global divide in access, driven by high costs and aggressive patent protections.

What is Keytruda and Why Does It Matter?

First approved in 2014, Keytruda (pembrolizumab) is an immunotherapy drug. Unlike traditional chemotherapy, which attacks cells directly, immunotherapy enables the patient’s own immune system to identify and attack cancer cells. This approach has extended survival for millions of people and is now approved for at least 19 different types of tumors, turning some previously fatal diagnoses into manageable conditions.

The drug’s efficacy has made it a commercial juggernaut. Keytruda has generated $31.7 billion in revenue, cementing its status as one of the best-selling drugs in pharmaceutical history.

The “Cancer Calculus”: Pricing and Patent Barriers

Even as the science behind Keytruda is a triumph, its distribution is a point of contention. An investigation coordinated by the International Consortium of Investigative Journalists (ICIJ), involving 124 journalists across 37 countries, suggests that the manufacturer, Merck & Co., has used a “fortress of patents” and lobbying to maintain high prices and protect its revenue.

This pricing strategy creates a “cancer calculus” where the ability to survive often depends on a patient’s geography or income. In the United States, analysis shows that people with median incomes struggle to afford the treatment. In other regions, the impact is even more severe, with hospitals forced to ration treatment and patients relying on crowdfunding or legal action to gain access.

Key Takeaways: The Access Gap

• Financial Barriers: High official market prices shut out patients in low- and middle-income regions.
• Systemic Strain: Health care systems worldwide are strained by the cost of providing this life-saving therapy.
• Regulatory Hurdles: Patent protections and regulatory frameworks often prevent the entry of more affordable alternatives.

The Rise of the Black Market and Counterfeit Risks

When legal channels become unaffordable, desperate patients often turn to the gray or black market. This has led to dangerous consequences, particularly in India. An investigation by The Indian Express found a growing market for counterfeit Keytruda.

In one instance, a patient in Punjab purchased 12 vials at a “discount” for approximately Rs 16 lakh. It was later discovered that the drugs were counterfeit and filled with antifungal medication instead of the immunotherapy drug. This black market is fueled by a nexus of pharmacists and fixers who employ authentic batch numbers and used vials to deceive patients. While the official market price for a 100 mg vial exceeds Rs 1.5 lakh, the lack of affordable access continues to push patients toward these high-risk alternatives.

Conclusion: The Path Forward

Keytruda represents a therapeutic milestone, but its legacy is complicated by the inequality of its distribution. The tension between pharmaceutical profitability and the human right to health care remains a critical fault line in global medicine. As cancer incidence is expected to rise—with projections suggesting a more than 70% increase in India by 2045—the need for sustainable pricing and accessible regulatory frameworks becomes an urgent global priority.